Corcept Therapeutics Incorporated (CORT)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 98.39% | 98.44% | 98.49% | 98.54% | 98.66% | 98.65% | 98.65% | 98.67% | 98.66% | 98.68% | 98.67% | 98.62% | 98.56% | 98.53% | 98.51% | 98.54% | 98.42% | 98.38% | 98.29% | 98.17% |
| Operating profit margin | 20.29% | 22.81% | 22.46% | 23.29% | 22.24% | 21.80% | 23.09% | 24.34% | 28.03% | 31.89% | 33.44% | 34.61% | 34.01% | 33.53% | 31.13% | 32.38% | 36.23% | 37.27% | 40.14% | 38.93% |
| Pretax margin | 23.92% | 26.46% | 26.30% | 26.95% | 25.82% | 24.89% | 25.38% | 26.04% | 28.91% | 32.35% | 33.66% | 34.70% | 34.16% | 33.74% | 31.51% | 33.03% | 37.19% | 38.55% | 41.65% | 40.55% |
| Net profit margin | 20.84% | 22.48% | 22.12% | 22.54% | 22.00% | 20.31% | 22.10% | 22.84% | 25.24% | 29.39% | 28.76% | 29.41% | 30.74% | 30.17% | 28.45% | 29.23% | 29.96% | 30.73% | 32.49% | 31.64% |
Corcept Therapeutics Incorporated has shown consistently high levels of profitability based on its profitability ratios. The gross profit margin has remained very strong, consistently above 98% throughout the reported period. This indicates that the company is efficiently managing its production and distribution costs.
The operating profit margin, though showing some fluctuations, has generally been healthy. It started above 38% in March 2020, peaked at around 40% in June 2020, and then fluctuated between 20-35% up to December 2024. This shows the company's ability to generate profits from its core operations.
The pretax margin, which represents the company's earnings before taxes, also demonstrates a positive trend. It started above 40% in March 2020, decreased gradually over time but remained above 20%, showing that the company is effective in managing its operating expenses and taxes.
The net profit margin, which reflects the company's overall profitability, has slightly decreased over the period but remained above 20% generally. This indicates that after accounting for all expenses, including taxes, Corcept Therapeutics Incorporated is still able to generate healthy profits.
Overall, the profitability ratios suggest that Corcept Therapeutics Incorporated has been successful in maintaining high levels of profitability and efficiency in its operations.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 16.29% | 18.28% | 17.90% | 18.59% | 17.26% | 16.52% | 18.85% | 16.30% | 19.31% | 23.78% | 26.41% | 28.11% | 29.37% | 20.21% | 18.79% | 19.94% | 22.42% | 24.85% | 28.32% | 29.26% |
| Return on assets (ROA) | 16.74% | 18.02% | 17.63% | 17.99% | 17.08% | 15.38% | 18.03% | 15.30% | 17.38% | 21.92% | 22.71% | 23.89% | 26.55% | 18.18% | 17.17% | 18.00% | 18.54% | 20.48% | 22.92% | 23.79% |
| Return on total capital | 20.04% | 22.32% | 21.39% | 22.07% | 20.83% | 20.88% | 23.08% | 18.88% | 22.44% | 26.79% | 29.64% | 32.27% | 33.12% | 21.90% | 20.44% | 21.56% | 24.50% | 27.10% | 31.08% | 31.84% |
| Return on equity (ROE) | 20.70% | 22.12% | 21.13% | 21.54% | 20.95% | 19.79% | 22.44% | 17.84% | 20.21% | 24.69% | 25.49% | 27.43% | 29.94% | 19.71% | 18.67% | 19.46% | 20.26% | 22.34% | 25.15% | 25.88% |
Corcept Therapeutics Incorporated's profitability ratios show a positive trend over the assessed periods. The Operating return on assets (Operating ROA) has declined from 29.26% in March 2020 to 16.30% in March 2023, with a slight increase to 18.28% by September 2024. This ratio indicates how well the company generates profits from its assets through its core operations.
The Return on assets (ROA) has also shown a decreasing trend from 23.79% in March 2020 to 16.74% in December 2024. This ratio reflects the company's overall efficiency in generating profits from its assets, which has been reducing over time.
Return on total capital provides an insight into how efficiently the company is using all its capital to generate profits. This ratio for Corcept Therapeutics Incorporated decreased from 31.84% in March 2020 to 20.04% by December 2024, showing a declining trend in capital efficiency.
Lastly, the Return on equity (ROE) measures the return on shareholder equity and has decreased steadily from 25.88% in March 2020 to 20.70% by December 2024. This indicates a decline in the company's ability to generate profits from shareholders' investments.
In summary, Corcept Therapeutics Incorporated has experienced a decrease in profitability ratios over the examined periods, signaling a potential need for improved operational efficiency and capital utilization to enhance overall profitability.